A Phase I/II Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs GSK 5733584 (Primary) ; Antineoplastics
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors GSK
- 03 Feb 2025 New trial record